The global in vitro lung model market comprises of products involved in development of viable models of human lungs for pharmaceutical and chemical testing applications. In vitro lung models provide an alternative to animal testing methods and help evaluate potential toxicity and efficacy of new drug formulations in a life-like pulmonary environment. Rapid adoption of 3D lung cultures and microfluidic models to better simulate physiology and metabolism of living lungs is expected to drive the market expansion during the forecast period.
The Global in vitro lung model market is estimated to be valued at US$ 245.0 Mn in 2024 and is expected to exhibit a CAGR of 14% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the global in vitro lung model market are Epithelix, MATTEK, Lonza, Emulate, AlveoliX AG, Nortis, CN Bio Innovations Ltd, MIMETAS, InSphero, ATTC Global, Tissuse GmbH and Cn Bio Innovations Limited. These players are focussing on new product launches and strategic collaborations to expand their reach.
Key opportunities in the market include growing research on developing microfluidic models that mimic complex physiological process in lungs along with incorporation of bioengineering methods to create lung chips with integrated functionalities.
Global expansion of various companies in this field has increased through partnerships and joint ventures. For instance, InSphero partnered with Axolotl Biosciences to develop 3D lung technologies while ATTC Global expanded its testing facilities in Asia Pacific and Europe to meet rising localized demand.
Market drivers:
- Stringent regulatory mandates favoring alternatives to animal testing for drug development and chemical toxicity evaluation.
- Growing R&D investments by pharmaceutical companies in developing personalized medicine and modeling chronic pulmonary disease.
Market restraints:
- High costs associated with development and maintenance of advanced 3D lung models.
- Technical challenges in fabrication of complex lung microstructures and recreating native cellular heterogeneity.
Segment Analysis
The Global In Vitro Lung Model Market Size is segmented on the basis of product type, application type and end use. By product type, the alveolar model segment dominates the market and is expected to continue its dominance during the forecast period. Alveolar models that can replicate and resemble the functioning and conditions of human alveoli enabling critical evaluation of inhaled therapeutics and toxicological assessment leading to its wide use. By application, toxicology testing segment holds largest market share attributed to rising focus on developing alternatives to animal testing for drug development and safety evaluation. Regarding end use, pharmaceutical & biotechnology companies are the key end users and are expected to dominate the market owing to extensive research in evaluating drug delivery, efficacy and toxicity at pre-clinical stages.
Regional Analysis
North America dominates the global in vitro lung model market. It is expected to continue its dominance during the forecast period as well due to presence of major players, growing focus on research activities for drug development and safety testing, and increasing awareness about alternatives to animal testing. Asia Pacific is expected to witness highest growth rate over the forecast period. Factors such as rising geriatric population leading to higher disease prevalence, increasing research funding, presence of less stringent regulations, and expansion of global players into developing nations are contributing to its rapid growth.
Get more insights on This Topic- Global In Vitro Lung Model Market
